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The Role and Management of Statins 
in Dyslipidemia and Addressing 
Patient Barriers to Use
Objectives
• Define the role of statins for patients with diabetes
• Recommend appropriate statin therapy with evidence-based 
indications from recent guidelines
• Adjust statin therapy based on barriers encountered with myopathy 
and other health concerns
• Describe alternatives to statin therapy
The US Diabetes “Epidemic”
• National prevalence of diabetes (2010)
– Age ≥ 20 years: 11.3% (25.6 million)
– Age ≥ 65 years: 26.9% (10.9 million)
• National prevalence of prediabetes (2010)
– Age ≥ 20 years: 35% (estimated 79 million)
– Age ≥ 65 years: 50%
CDC National Diabetes Fact Sheet 2011
Complications of Diabetes
Macrovascular
Microvascular
Macrovascular Complications
Heart Disease and Stroke
Americans with Diabetes ≥ 35 yo (2011)
• 5 million with heart disease
• 3.7 million with other heart  
“condition”
• 2.1 million with reported stroke
• 7.6 million with heart disease or 
stroke
http://www.cdc.gov/diabetes/statistics/cvd/fig1.htm
Heart Disease and Stroke
• Diabetes-related death certificates in people ≥ 65 yo (2004)
– Heart disease noted in 68%
– Stroke noted in 16%
• Risk
– Heart disease death rates and risk of stroke are 2 - 4 times higher in 
adults with diabetes vs. those without diabetes
CDC National Diabetes Fact Sheet 2011
CHD and Diabetes
• CVD is the major cause of morbidity and mortality in patients with 
diabetes 
• Dyslipidemia and hypertension are clear risk factors
– Many studies have shown benefit in controlling these to prevent or 
slow CVD in diabetes
Buse JB. Diabetes Care 2007
Gaede P. N Engl J Med 2008
Why We Care About Statins
Lipid Guidelines
Review of NCEP ATP III
Highlights of the new 2013 ACC/AHA Blood Cholesterol Guidelines
ADA Guidelines
NCEP ATP III
Released: 2001
Updated: 2004
Goal Values or Targets
• TC < 200 mg/dL
• HDL > 40 mg/dL (>50mg/dL for women)
• TG < 150 mg/dL
• LDL goal must be determined based on risk
NCEP ATP III Expert panel. JAMA  2001; 285(19):2486-97.
NCEP ATP III Guidelines 
“LDL is the major atherogenic lipoprotein and has long been identified by NCEP 
as the primary target of cholesterol-lowering therapy”
“This focus on LDL has been strongly validated by recent clinical trials, which 
show the efficacy of LDL-lowering therapy for reducing risk for CHD”
NCEP ATP III Expert panel. JAMA  2001; 285(19):2486-97.
NCEP ATP III Guidelines
NCEP ATP III Expert panel. JAMA  2001; 285(19):2486-97.
Risk Category
CHD and CHD risk
equivalents
Multiple (2+) risk factors
Zero to one risk factor
LDL Goal (mg/dL)
<100
<130
<160
Three Categories of Risk that Modify 
LDL-Cholesterol Goals
NCEP ATP III Expert panel. JAMA  2001; 285(19):2486-97.
LDL Cholesterol Goals and Cutpoints for Therapeutic Lifestyle 
Changes (TLC) and Drug Therapy in Different Risk Categories
Risk Category
LDL Goal
(mg/dL)
LDL Level at Which to 
Initiate Therapeutic 
Lifestyle Changes (TLC) 
(mg/dL)
LDL Level at Which 
to Consider
Drug Therapy 
(mg/dL)
CHD or CHD Risk 
Equivalents
(10-year risk >20%)
<100 
(optional <70)
≥100 ≥100 (<100: consider drug options)
2+ Risk Factors 
(10-year risk ≤20%) <130 ≥130
10-year risk 10–20%: 
≥130 
(100-129: consider drug 
options)
10-year risk <10%: ≥160 
0–1 Risk Factor <160 ≥160
≥190 
(160-189: LDL-lowering drug 
optional) 
NCEP ATP III Expert panel. JAMA  2001; 285(19):2486-97. Grundy SM. Circulation. 110:227-39;2004
Optional LDL Goal < 70 mg/dL
• Option for patients at “very high risk”
– Must have established CVD plus any of:
• Multiple major risk factors (especially diabetes)
• Severe and poorly controlled risk factors (especially cigarette 
smoking)
• Multiple risk factors of Metabolic Syndrome
– High TG > 200 mg/dL plus
– Non-HDL ≥ 130 mg/dL with low HDL < 40 mg/dL
• History of acute coronary syndromes (ACS)
Grundy SM. Circulation. 110:227-39;2004
Not Good Enough?
• “Half of all myocardial infarctions and strokes occur despite 
apparently healthy men and women with LDL levels below 
currently recommended thresholds for treatment”
• “Even with adequate LDL lowering, many patients on statin 
therapy have significant CVD risk”
Ridker PM. Lancet. 2009; 373:1175-82. 
Brunzell JD. Diabetes Care. 2008; 31:811-22
2013 ACC/AHA Guideline on the 
Treatment of Blood Cholesterol to 
Reduce Atherosclerotic 
Cardiovascular Risk in Adults
Released Mid-November 2013
Journal of the American College of Cardiology 
Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal of the American College of Cardiology. 
2013:doi:10.1016/j.jacc.2013.11.002.
2013 ACC/AHA Blood Cholesterol 
Guidelines
• Expert panel for ATP 4
• Partnered with ACC/AHA
• Focus on ASCVD risk reduction, not comprehensive lipid 
management
• Only used RCT, systematic reviews, meta-analyses of RCT
3 Critical Questions
1. What is the evidence for LDL and non-HDL goals for the 
secondary prevention of ASCVD?
2. Same as #1, but primary prevention
3. For primary and secondary prevention, what is the impact on 
lipid levels, effectiveness, and safety of specific cholesterol-
modifying drugs used for lipid management in general and in 
selected subgroups?
Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal of the American College 
of Cardiology. 2013:doi:10.1016/j.jacc.2013.11.002.
Findings
• “unable to find evidence to support titrating statins to a target LDL 
or non-HDL goal”
• “extensive evidence that appropriate statin intensity should be 
used to reduce ASCVD risk”
• “use of non-statins to additionally lower non-HDL once LDL goal 
achieved, DID NOT further reduce ASCVD outcomes”
Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal of the American College 
of Cardiology. 2013:doi:10.1016/j.jacc.2013.11.002.
Findings
• Non-statin therapies in general have not demonstrated significant 
ASCVD event reduction.
• Lifestyle modifications remain a critical component of health 
promotion and ASCVD risk reduction
• Identification of 4 statin benefit groups to focus on ASCVD risk 
reduction
Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal of the American College 
of Cardiology. 2013:doi:10.1016/j.jacc.2013.11.002.
4 Statin Benefit Groups
• Clinical ASCVD ≤ 75 yo (secondary prevention)
• Primary elevation of LDL ≥ 190 mg/dL
• 40-75 yo with Diabetes and LDL 70-189 mg/dL
• No clinical ASCVD or Diabetes, 40-75 yo and LDL 70-189 mg/dL and 
10-year ASCVD risk of 7.5% or higher
Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal of the American College 
of Cardiology. 2013:doi:10.1016/j.jacc.2013.11.002.
Stone. 2013 ACC/AHA Blood 
Cholesterol Guideline. Journal of 
the American College of 
Cardiology. 
2013:doi:10.1016/j.jacc.2013.11.0
02.
Clinical ASCVD ≤ 75 years
• High-intensity statin therapy (1st line)
• If not tolerated, use moderate-intensity
• If > 75 years, consider benefits vs risks and may use moderate-
or high-intensity statin
Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal of the American College of 
Cardiology. 2013:doi:10.1016/j.jacc.2013.11.002.
LDL ≥ 190 mg/dL
• High-intensity statin therapy
• If not tolerated, use maximum tolerated intensity
• Once maximum intensity achieved, may consider addition of non-
statins to further lower LDL (weak data—expert opinion)  
Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal of the American College of 
Cardiology. 2013:doi:10.1016/j.jacc.2013.11.002.
40-75 years with Diabetes and LDL 
70-189 mg/dL
• Moderate-intensity statin therapy
• If ASCVD 10-year risk ≥ 7.5%, use high-intensity
• If < 40 or > 75 years, consider benefits vs risks and patient 
preferences
Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal of the American College of 
Cardiology. 2013:doi:10.1016/j.jacc.2013.11.002.
No Clinical ASCVD or Diabetes, 40-75 
yo and LDL 70-189 mg/dL and 10-year 
ASCVD Risk of 7.5% or Higher
• Moderate- to High-intensity statin therapy
Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal of the American College 
of Cardiology. 2013:doi:10.1016/j.jacc.2013.11.002.
Adults with LDL <190 mg/dL not 
Fitting into a Statin Benefit Group
• Additional factors may be considered to inform treatment decision 
making
– LDL ≥ 160 mg/dL
– Genetic hyperlipidemia
– Family history of premature ASCVD ♂< 55 years or ♀< 65 years
– High C-reactive Protein (CRP) > 2 mg/L
– Coronary artery calcium score ≥ 300 Agatston units or ≥ 75 
percentile for age, sex, ethnicity
– ABI <0.9
– Lifetime risk of ASCVD
Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal of the American College 
of Cardiology. 2013:doi:10.1016/j.jacc.2013.11.002.
Intensity of Statin Therapy
• Expected LDL-lowering:
– High-intensity ≥ 50%
– Moderate-intensity 30 to < 50%
– Low-intensity < 30%
• High-intensity reduces ASCVD risk more
• However, moderate- or low-intensity still provides protection, just 
not as much as high-intensity 
Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal of the American College 
of Cardiology. 2013:doi:10.1016/j.jacc.2013.11.002.
Statin Intensity Categories 
and Drugs
High-intensity Moderate-intensity Low-intensity
Atorvastatin 40-80 mg Atorvastatin 10-20 mg Simvastatin 10 mg
Rosuvastatin 20-40 mg Rosuvastatin 5-10 mg Pravastatin 10-20 mg
Simvastatin 20-40 mg Lovastatin 20 mg
Pravastatin 40-80 mg Fluvastatin 20-40 mg
Lovastatin 40 mg Pitavastatin 1 mg
Fluvastatin XL 80 mg
Fluvastatin 40 mg BID
Pitavastatin 2-4 mg
Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal of the American College 
of Cardiology. 2013:doi:10.1016/j.jacc.2013.11.002.
Patient is a 58 YO male with diabetes and an LDL of 198 mg/dL.  
Per the 2013 ACC/AHA guidelines, how should he be treated?
A. Pravastatin 80 mg
B. Rosuvastatin 20 mg
C. Atorvastatin 20 mg
D. Fluvastatin 40 mg
Case Question 1
Patient is a 62 YO female with diabetes, an LDL of 82 (on no 
statin), and an ASCVD 10-year risk of 7.8%.  Per 2013 ACC/AHA 
guidelines, how should she  be treated?
A. Atorvastatin 80 mg
B. Pitavastatin 1 mg
C. Lovastatin 20 mg
D. Pravastatin 80 mg
Case Question 2
Calculation of ASCVD 10-year Risk (%)
• Pooled Cohorts Equations
– Calculates risk of CHD death, fatal or non-fatal MI or stroke
– Used for “white and black men and women” without clinical 
ASCVD
– Controversial calculation
• This places many more people in higher risk categories than 
the Framingham Risk tool
Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal of the American College 
of Cardiology. 2013:doi:10.1016/j.jacc.2013.11.002.

Statin Safety Recommendations
• Moderate-intensity statin should be used instead of high-intensity 
if high risk of statin-associated adverse effects
– Impaired renal or hepatic function
– Previous stain intolerances or muscle disorder
– ALT > 3 times upper limit of normal (CI)
– On drugs that affect statin metabolism
– > 75 years of age
– Possibly history of hemorrhagic stroke
– Possibly Asian ancestry
Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal of the American College 
of Cardiology. 2013:doi:10.1016/j.jacc.2013.11.002.
Statin Safety Recommendations
• Monitor creatine kinase (CK or CPK)
– Baseline and if myopathy symptoms
• Monitor ALT (liver function)
– Baseline and if hepatotoxic symptoms
• Consider ↓ statin dose if 2 consecutive LDL < 40 mg/dL
• Avoid simvastatin 80 mg
• Evaluate for new onset diabetes
Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal of the American College 
of Cardiology. 2013:doi:10.1016/j.jacc.2013.11.002.
Monitoring Statin Therapy
• Initial fasting lipid panel (then start drug)
• Check fasting lipid panel 4-12 weeks (often 6-8 weeks); to check 
adherence, NOT to achieve a target or goal
• Then check fasting lipid panel 3-12 months
Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal of the American College 
of Cardiology. 2013:doi:10.1016/j.jacc.2013.11.002.
Monitoring Statin Therapy
• Insufficient response to statin dose
– Reinforce adherence to medication and lifestyle
– Exclude secondary causes
– If higher-risk ASCVD patients on max statin dose, may consider 
adding non-statin
• Clinical ASCVD < 75 years
• Baseline LDL ≥ 190 mg/dL
• 40-75 years old with diabetes
Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal of the American College 
of Cardiology. 2013:doi:10.1016/j.jacc.2013.11.002.
Summary of Lipid Guideline 
Differences
ATP 3
• Focus on LDL goals
• Use statins or any lipid-
lowering drugs to attain goal
2013 ACC/AHA
• Focus on statin intensity
• Use statins almost exclusively
ADA 2014 Standards of Care
• Statin therapy if LDL > 100 mg/dL
• Statin therapy regardless of baseline lipid levels in DM:
– With overt CVD
– Without CVD, > 40 yoa, ≥ 1 CVD risk factor
• If LDL goal of < 100 mg/dL is not reached with optimal statin dosing, 
an LDL reduction of 30 - 40% from baseline is an alternative 
therapeutic goal
• “Combination drug therapy has been shown not to provide additional 
cardiovascular benefit above statin therapy alone and is not generally 
recommended.”
ADA 2014 Standards of Medical Care
ADA 2015 Standards of Care
• High-intensity statin
– All ages with DM and overt CVD 
– 40-75 yo DM with additional CVD risk
• Moderate- or High-intensity 
statin
– <40 yo DM with additional CVD risk
– >75 yo DM with additional CVD risk
• Moderate-intensity statin
– 40-75 yo DM without additional CVD risk
– >75 yo DM without additional CVD risk 
• Adjust statin intensity based on 
patient response (AE, LDL)
• Lipid panel for monitoring 
adherence 
• “Combination therapy has not 
been shown to provide 
additional CVD benefit above 
statin therapy alone and is not 
generally recommended”
ADA 2015 Standards of Medical Care
Statin Myopathy
Statin Mechanism of Action
Reduces hepatic cholesterol synthesis, lowering intracellular 
cholesterol, which stimulates upregulation of LDL receptors and 
increases the uptake of non-HDL particles from the systemic circulation
Definitions of Statin Myopathy
• Myopathy
– Any muscle complaint related to statin use
• Myalgia
– Muscle symptoms without elevated creatine kinase (CK)
• Myositis
– Elevated serum CK with or without muscle symptoms
• Rhabdomyolysis
– Severe muscle symptoms with CK elevated > 10 times the upper 
limit of normal (ULN)
Pasternak RC, et al. ACC/AHA/NHLBIL Clinical advisory on the 
use and safety of statins. Journal of the American College of 
Cardiology, 2002.
Characteristics of Statin Myopathy
• Localization: Generalized (60%) or localized to large proximal 
muscle groups. Lower extremities more frequently (25%) affected 
than upper (8%)
• Type: Heaviness, stiffness, cramps
• “Equivalent” of muscle pain: Weakness, tendonitis
• Frequency and duration: Usually intermittent lasting several 
minutes to hours
• Timing: < 1 month to several years
Pasternak RC, et al. ACC/AHA/NHLBIL Clinical advisory on the 
use and safety of statins. Journal of the American College of 
Cardiology, 2002.
Statin Myopathy – Randomized 
Controlled Trials (RCT)
• Rarely reported in RCTs
– RCT reported 1-5% of patients experiencing myalgia
– Patients are carefully selected for RCT
• Patients with renal or hepatic insufficiency, poorly controlled 
diabetes, history of muscle complaints, and taking drugs with 
possible drug interactions usually excluded from trials
– Most studies focus on reporting rhabdo vs. myalgia
– Lack of consensus on definitions
Pasternak RC, et al. ACC/AHA/NHLBIL Clinical advisory on the 
use and safety of statins. Journal of the American College of 
Cardiology, 2002. 
Statin Myopathy – Observational 
Studies Outpatient
• Higher frequency of myopathy
– 9-20%
• PRIMO Study
– 10.5%
Pasternak RC, et al. ACC/AHA/NHLBIL Clinical advisory on the use and safety of statins. 
Journal of the American College of Cardiology, 2002. Bruckert E, et al. Mild to moderate 
muscular symptoms with dosage statin therapy, PRIMO. Cardiovascular Drugs and 
Therapy, 2006.
What Causes Statin Myopathy
Carrier of 
SLCO1B1 
gene 
polymorphisms
Drug or food 
interactions 
(CYP3A4, 
CYP2C9, UGT, 
OAT1B1)
Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. 
JAMA. 2003;289:1681–1690). HMG-CoA=3-hydroxy-3-
methylglutaryl coenzymeA
Pharmacotherapy Considerations
Medication Lipophilicity Metabolism Half-life Metabolites
Rosuvastatin Hydrophilic CYP2C9 ~21 Minor active 
metabolite
Atorvastatin Lipophilic CYP3A4 ~15-30 Active metabolite
Simvastatin Lipophilic CYP3A4 ~2-3 Active metabolite
Pitavastatin Lipophilic CYP3A4 ~12 No active 
metabolite
Lovastatin Lipophilic CYP3A4 ~3 Active metabolite
Pravastatin Hydrophilic Sulfation ~1-3 No active
metabolite
Fluvastatin Lipophilic CYP2C9 ~5 No active 
metabolite

Statin Toxicity
• Simvastatin 40-80mg – 18.2%
• Atorvastatin 40-80mg – 14.9%
• Pravastatin 40mg – 10.9%
• Fluvastatin XL 80mg – 5.1%
Pasternak RC, et al. ACC/AHA/NHLBIL Clinical advisory on the use and safety of statins. 
Journal of the American College of Cardiology, 2002. Bruckert E, et al. Mild to moderate 
muscular symptoms with dosage statin therapy, PRIMO. Cardiovascular Drugs and 
Therapy, 2006.
Risk Factors for Statin Myopathy
Endogenous Risks
• Advanced age (>65)
• Low BMI and frailty
• Multisystem disease 
• Hypothyroidism
• Hypertriglyceridemia
• Metabolic muscle disease
• Family history of muscular 
symptoms
• History of elevated CK or 
muscle symptoms
Exogenous Risks
• Alcohol consumption
• Heavy exercise
• Surgery with severe 
metabolic demands
• >1 L grapefruit juice daily
• Drug interactions
Pasternak RC, et al. ACC/AHA/NHLBIL Clinical advisory on the use and safety of statins. Journal of the American College of 
Cardiology, 2002. Chatzizisis YS, et al. Risk factors and drug interactions predisposing to statin-induced myopathy. Drug Safety, 2010.
Drugs Affecting CYP450 (3A4)
• Cyclosporine
• Nondihydropyridine Calcium Channel Blockers (i.e. verapamil, 
diltiazem)
• Amiodarone
• Azole antifungals (i.e. fluconazole)
• Colchicine
• Digoxin
• Protease inhibitors
• Warfarin
• Macrolide antibiotics (i.e. azithromycin)
Lexi-Comp.
Drugs Affecting CYP450 (2C9)
• Azole antifungals (i.e. fluconazole)
• H2 receptor antagonists (i.e. ranitidine)
• Proton pump inhibitors (i.e. omeprazole)
• Warfarin
• NSAIDs
• Sulfonylureas (i.e. glipizide)
• ARBs
• Amiodarone
Lexi-Comp.
Gemfibrozil
• Inhibits glucuronidation of UGT
• Inhibits the OATP1B1 transporter
– Increased levels of statin and increased risk of adverse effects
Lexi-Comp. UGT: uridine diphosphate-glucuronosyl transferases
Simvastatin
• SEARCH trial – 80mg vs. 20mg
– Major CV events 24.5% vs. 25.7%
– Myopathy (CK>10x ULN + symptoms)
• 52 patients on 80mg; 1 patient on 20mg
– Rhabdomyolysis (CK>40x ULN + symptoms)
• 22 patients on 80mg; 0 patients on 20mg
– Risk declines from 5 to 2/1000 person years in the first 12 
months, then from 1 to 0.4/1000 per years after 12 months
– Risk of myopathy found to be 3x higher and risk of fatal 
rhabdomyolysis higher than with more potent LDL lowering drugs 
atorvastatin and rosuvastatin
Lancet. 2010;376:1658-69.
Simvastatin Dosing Restrictions
• 80mg restricted to those taking it >12 months prior to 6/8/2011
• Maximum dose of simvastatin established when used concomitantly 
with other drugs:
Drug Simvastatin Max Dose
Amiodarone 20mg
Amlodipine 20mg
Diltiazem 10mg
Verapamil 10mg
Lexi-Comp.
Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. 
JAMA. 2003;289:1681–1690). HMG-CoA=3-hydroxy-3-
methylglutaryl coenzymeA
CoEnzyme Q10 Supplementation
• Bookstaver and colleagues
– CoQ10 60mg twice daily
– No more effective than placebo in decreasing muscle pain that 
was presumed to be statin induced
• Kelly and colleagues
– CoQ10 100mg/day
– Myopathic pain improved from baseline in treated patients
• Ganesan and colleagues
– Relationship of GLUT4 protein levels, CoQ10, and statins
Bookstaver D.  Am J Cardiol 2012;110:526-29. Marcoff L. J Am Coll Cardiol. 2007;49:2231-7.
Ganesan S. Metab Syndr Relat Disord 2013. Kelly P. J Am Coll Cardio 2005;45.
CoEnzyme Q10
• Dose: 100-300mg/day in divided doses
• Adverse Effects: (<1%) nausea/vomiting, diarrhea, elevated 
transaminases (rare)
• Drug Interactions: diminished effect of warfarin
• Rated as ‘Likely Safe’
Natural Medicines Comprehensive Database
Management of Myopathy
• Muscle symptoms
– Stop statin (2-6 week drug holiday)
– Measure CK, serum creatinine and urinalysis
• Symptoms resolve
– Restart original statin at same or lower dose
– If recurrence, stop original statin
– When symptoms resolve, start new statin at a lower dose
• If not resolved > 2 months, likely not statin; resume original dose
• If intolerant of statins, may use non-statin
Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal of the American College 
of Cardiology. 2013:doi:10.1016/j.jacc.2013.11.002.
Alternate Statin Dosing
• Use a lower toxicity statin
– Fluvastatin XL 80mg (39% LDL lowering potential)
• Use a statin with less CYP450 dependence
– Pravastatin
• Use alternate day or once/twice weekly dosing with longer acting 
statins (rosuvastatin, atorvastatin, pitavastatin)
– 35% LDL lowering with rosuvastatin 5mg every other day
– 26% LDL lowering with rosuvastatin 5-10mg twice weekly
Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal of the American College 
of Cardiology. 2013:doi:10.1016/j.jacc.2013.11.002.
Statin Discontinuation
• Retrospective cohort study: 107,835 patients over 9 years
• Statin discontinued: 57,292 (53%)
• Statin-related events: 18,778 (17.4%)
• Findings: 
– Of 11,124 who discontinued, 6579 were re-challenged with statin 
over next 12 months
– 92.2% were still taking statin after 12 months
– 2721 who were re-challenged with same statin, 1295 were still 
taking 12 months later
Zhang H et al. Ann Intern Med. 2013;158:526-534. 
Bottom Line
• Most patient re-challenged can tolerate statins long-term
– Statin-related events may have other causes, are tolerable or may 
be specific to individual statins rather than the entire drug class
• If patients develop muscle symptoms after start
– Determine likelihood that muscle symptoms are due to the statin
– Balance of expected statin therapy with the likelihood that muscle 
symptoms are due to statin
Zhang H et al. Ann Intern Med. 2013;158:526-534. 
Case Question 3
• 45 YO Male with past medical history: hypertension, type 2 diabetes, obesity and 
smoker complaining of muscle pain
• Labs: ALT/AST WNL and CK 350
• ASCVD risk is 9%
• Medications: Metformin 500 mg 1 tablet twice daily, Lisinopril 40mg daily, HCTZ 25mg 
daily, amlodipine 10mg, and simvastatin 40mg once daily
(History of being started on atorvastatin 80mg once daily but complained of   
muscle pain shortly after. PCP immediately switched to simvastatin 40mg.)
Which of the following is the best recommendation:
A. Change statin therapy to bile acid sequestrant
B. Decrease simvastatin to 20mg once daily
C. Provide a 6-week statin drug holiday and re-challenge with atorvastatin 40mg
D. Discontinue simvastatin and start rosuvastatin 20mg
Other Statin Concerns
Statin and Diabetes
• JUPITER
– N=17,802
– 27% increase in risk of diabetes (p=0.01)
– 39% reduction in primary endpoint (MI, stroke, CV deaths) for 
patients with diabetes risk factors and 52% reduction in those 
that with no risk factors
– 134 vascular deaths avoided for every 54 new cases of diabetes
• Meta-analysis (PROVE IT-TIMI 22, TNT, IDEAL, A to Z, SEARCH)
– High-dose statins (atorvastatin and simvastatin) increased risk of 
diabetes (OR 1.12)
PROVE-IT TIMI 22. Circulation 2004; Sattar N. Lancet 2010;375:735-42; Preiss
D. JAMA 2011;305:2556; Rajpathak SN. Diabetes Care 2009;32:1924.
Statins and Cognitive Impairment / 
Dementia
• Meta-analysis evaluating 16 studies: Without baseline cognitive 
dysfunction, no effect on cognition
– Long-term data may support beneficial role for statins in 
prevention of dementia (HR 0.71, CI 0.61-0.82)
– 5 studies showed 29% reduction in incidence of dementia
• Prospective study of 6,600 patients: Patients with normal 
cognitive function or mild cognitive impairment and statin use 
performed better on attention measures and had slower annual 
worsening of Clinical Dementia Rating Sum of Boxes  (P<0.006)
– No difference in cognitive decline
Steenland K. Journal of American Geriatric Society 2013. 
61(9):1449-55; Swiger KJ. Mayo Clinic Proceedings 2013
Statins and Acute Kidney Injury
• Retrospective analysis of > 2 million patients on moderate to high 
intensity statins:
– Rosuvastatin ≥ 10mg
– Atorvastatin ≥ 20mg
– Simvastatin ≥ 40mg
• 34% greater risk of hospitalization for acute kidney injury (AKI) in 
first 120 days of treatment with statin (CI 1.25-1.43)
– NNH was 1700 for 1 AKI hospitalization within the 120 days
• Retrospective analysis of > 3 million patients on statin, no increase 
in AKI as a whole
– simvastatin 40-80mg have increased risk of AKI
Dormuth CR. BMJ 2013;346:f880; Layton JB. 
Pharmacoepidemiology and Drug Safety 2013;22:1061
Bottom Line
• Diabetes: cardiovascular benefits outweigh the small absolute risks 
of developing diabetes
• Dementia: there is no increased risk of cognitive decline, and there 
may even be a protective role
• Acute Kidney Injury: cardiovascular benefits of statin therapy 
outweigh the proposed risk of acute kidney injury
Dormuth CR. BMJ 2013;346:f880; Layton JB. 
Pharmacoepidemiology and Drug Safety 2013;22:1061
Drug Therapy Options
Statin Considerations
Adverse Effects
• Myopathy (rhabdomyolysis)
• Elevated liver transaminases (rare)
Contraindications
• Pregnancy, active liver disease
Monitor
• Fasting lipid profile (6 - 8 weeks)
• Baseline CPK (CK) and again if muscle pain
• Baseline LFT and again periodically  
Lexi-Comp. NCEP ATP III Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal 
of the American College of Cardiology. 2013:doi:10.1016/j.jacc.2013.11.002.
Statin Pearls
• Dose in evening unless long half-life (atorva-, rosuva-)
• Myopathy - rechallenge with lower dose or different statin
– Less with prava- (maybe rosuva- and pitava-)
– CoQ10, alternate dosing with long-half-life statins
• Drug interactions
– Many (CYP 3A4, 2C9)
– Less with pravastatin
• Recent label changes:
– No more simvastatin 80 mg
– Risk of diabetes, cognitive impairment, less liver monitoring, drug 
interactions
Lexi-Comp. NCEP ATP III Stone. 2013 ACC/AHA Blood Cholesterol Guideline. Journal 
of the American College of Cardiology. 2013:doi:10.1016/j.jacc.2013.11.002.
Non-Statin Therapy Options
• Fibrate
• Niacin
• Bile Acid Sequestrant
• Cholesterol absorption 
inhibitor
• Omega 3 fatty acid
• PCSK9 Monoclonal 
Antibodies (future)
• Complementary and 
Alternative Agents
• Cholestoff: Contains plant stanols and 
sterols (15 - 20% LDL lowering)
• Fish oil: 2000 - 4000 mg/day
• Soluble fiber: 10 - 25 g/day
• Red Yeast Rice: 1200 - 2400 mg 
contains lovastatin 2 - 6 mg 
equivalence (20 - 25% LDL lowering)
• CoEnzyme Q10: 100 - 300 mg/day
Patient Education
Health Literacy Sensitive Approaches
• Explain the differences between statins and about medication itself
– Patients also have fear of perceived adverse effects and have 
misunderstanding of the benefits
• Use an analogy that the patient can relate to
• Visual aids
• Plain language
• Relate to diabetes and have patient repeat back goals
Lemstra M, Blackburn D, et al. Proportion and risk indicators of nonadherence to 
statin therapy: a meta-analysis. Can J Cardiol. 2012;28:574-80.
Motivational Interviewing
• Identify what is important to them (e.g. family, grandkids)
• Involve patient with decision process (shared decision making)
– Mayo Clinic shared decision making tools
Lemstra M, Blackburn D, et al. Proportion and risk indicators of nonadherence to 
statin therapy: a meta-analysis. Can J Cardiol. 2012;28:574-80.
Complex Case 1
• 60 YO Male complaining of general pain with past medication history type 2 diabetes, 
HTN, dyslipidemia, CAD, MI, CABG, left carotid endarderectomy
Which of the following is the best recommendation:
A. Re-challenge statin with rosuvastatin 5mg every other day with coenzyme Q10 
supplementation
B. Re-challenge with pravastatin XXmg
C. Re-challenge with atorvastatin 40mg
D. Start bile acid sequestrant
Baseline 2 Weeks Later 6 weeks later
Statin Pravastatin 40mg None for 4 weeks None for 10 weeks
CPK (units/L) None 563 711
LDL (mg/dL) 96 122
Muscle Pain Present Not Resolved Not resolved
Plan Stop pravastatin No drug therapy ?
Complex Case 2
• 51 YO Male with past medical history: Dyslipidemia, hypertension, obesity, 
hypothyroid, coronary artery disease, type 2 diabetes
• Current labs (2015): TC 395, HDL 46, LDL 320, TG 145, AST/ALT 22/38, CK WNL
• Medication intolerances: complaints of myalgias with ALL statins (history of hospital 
admission in 2013 with AST/ALT 1100/1200, CK 50,000 on atorvastatin 40mg), 
gemfibrozil, fenofibrate, niacin, ezetimibe
• Not currently on treatment for his dyslipidemia
Which of the following is the best recommendation:
A. Re-challenge statin with rosuvastatin 5mg every other day with coenzyme Q10 
supplementation
B. Try CholestOff
C. Try fish oil
D. Start bile acid sequestrant
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